WebSep 27, 2024 · 人物介绍 Phil Chamberlain 在牛津大学获得了学士学位和博士学位,后前往美国诺华研究基金会基因组学研究所 (GNF)工作,期间领导了严重呼吸道和疾病的项目,并解决了多种药物新结构。 后于 2007年加入新基 (Celgene),建立并领导了结构和化学生物学部门,后担任蛋白质稳态和结构生物学执行董事。 在新基期间,Phil 完成了沙利度胺类似物 … WebJul 1, 2024 · P Chamberlain P 1. Author information. Affiliations. 1 author. 1. Celgene, San Diego, CA, USA. Nature Chemical Biology, 01 Jul 2024, 14(7): 639-640 DOI: 10.1038/s41589-018-0057-9 PMID: 29892082 . Share this article Share with email Share with twitter Share with linkedin Share with facebook. Abstract ...
A novel cereblon modulator recruits GSPT1 to the CRL4
WebApr 6, 2024 · Celgene Corporation, San Diego, CA, USA. ... Chamberlain PP, 0000-0002-6407-7344; Nature Structural & Molecular Biology, 06 Apr 2024, 27(4): 319-322 DOI: 10.1038/s41594-020-0405-9 PMID: 32251415 . Share this article Share with email Share with twitter Share with linkedin Share with facebook. Abstract . WebGet Phil Chamberlain's email address (c*****@hotmail.co.uk) and phone number (+44 7793 01....) at RocketReach. Get 5 free searches. Rocketreach finds email, phone & social media for 450M+ professionals. Try for free at rocketreach.co lowes yard work wagons w/wheels
SDEE: Founders Tales
WebJan 3, 2024 · NEW YORK & SUMMIT, N.J., January 3, 2024 – Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. … WebSep 16, 2024 · Main. Targeted protein degradation is an emerging therapeutic modality whereby small-molecule ligands are used to redirect the cellular protein homeostasis … WebPhil Chamberlain - Co-Founder, President and CEO - Neomorph, Inc. LinkedIn Phil Chamberlain Biotechnology leader in new modalities and targeted protein degradation … lowes yahoo finance stocks